As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
An Expert View from Danie du Plessis, executive vice president, pharmaceutical operations at Kyowa Kirin International, and chair of the Medical Affairs Professional Society (MAPS) board. 29 May 2024
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
In an Expert View column, Bruce Leuchter, chief executive of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company, outlines the importance of increased investment in research and development and innovative business models, to bring more therapies for neurological disorders to patients. 17 May 2024
A new age of innovation in immunology could change medical practice and people’s lives, as long as all parts of the system learn, evolve and work together, writes Anant Murthy, General Manager, argenx EMEA, in an Expert View piece. 1 May 2024
A second Expert View piece from Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex. 4 April 2024
Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex, provides an Expert View. 29 February 2024
In an Expert View piece, Mark Seymour, Director and Head of Media, Healthcare, at FleishmanHillard London, argues that in the ever-evolving world of healthcare, the rules of communications have not changed, they have just become more intricate, demanding a renewed focus on the essentials. 8 February 2024
An Expert View from Ross Maclean, Precision Health Economics, Outcomes Research and Head of Medical Affairs,
Precision Value and Health, and the same company's Jon Bambalas, Senior Vice President Business Development, Products Senior Vice President Business Development. 5 February 2024
An Expert View from Mark Doyle, co-founder of UK company The Method and creator of A Life in a Day experience, which seeks to support the pharmaceutical and healthcare industries in developing patient-centric strategies for more impactful engagement. 7 June 2021
AJ Ploszay, vice president of digital strategy, IQVIA, provides an Expert View on how the precedent for consumer buying set by companies like Amazon, further accelerated by the digital buying trends driven by COVID-19, are influencing a similar shift in the commercial pharma space. 20 May 2021
An Expert View from Manjit Singh, chairman of the Pharmaceutical Supply Chain Initiative, which tries to foster responsible supply chains, highlighting the issue of antibiotic resistance and the often-underestimated threat coming from the discharge of material in environment. 14 May 2021
Catherine Owen, senior vice president of major markets at Bristol Myers Squibb, provides an Expert View on why increasing female representation on corporate boards isn’t just a numbers game. Women bring diverse perspectives that are needed more than ever. 7 May 2021
Nicola Mahy, director at Align Strategy, makes the case for an integrated evidence plan to maximize patient access to a brand in an Expert View piece. 21 April 2021
Hannah Schofield, associate at Hogan Lovells, considers the option of utilizing blockchain technology for accurate tracking and monitoring in an Expert View piece. 7 April 2021
Debbie Bowen-Heaton, partner at Oliver Wight, provides an Expert View on how companies can prepare for the disruption Amazon's arrival in Europe's pharmaceutical space will bring. 23 March 2021
Catherine Penny, partner, and Laura Beagrie, professional support lawyer, Stevens & Bolton, consider an important issue brought to light by the scramble for coronavirus vaccines. 12 March 2021
Patrick Delavault, executive VP, scientific & medical affairs, LFB Biopharmaceuticals, provides an Expert View on how the pandemic has led to a focus on an important medicinal option for patients. 5 March 2021
Ambreen Farook, senior director, alliance management and program lead at Halozyme Therapeutics, provides an Expert View on the dos and don'ts of biopharmaceutical industry partnerships. 23 February 2021
The recent merger of Mylan and Upjohn was one of the biggest in healthcare. But in their rebirth as Viatris (Nasdaq: VTRS), a lesson about the future of the industry may be in rediscovering its humanity, writes Christina Falzano, managing director, Conran Design Group, in an Expert View piece. 19 February 2021
Sarah Ellson, co-head of regulatory and life sciences and healthcare lawyer, Fieldfisher and her colleague Laura Penny, associate and regulatory lawyer, provide an Expert View on the topical issue of the use of medicines off-label. 8 February 2021
COVID-19 has disrupted the traditional engagement model and demands a fundamental rethink of how pharma companies engage with their customers. But few players seem to be rising to the challenge, write Patrick Branch from LEK Consulting and Ludwig Kanzler from Hanegi LLC, in an Expert View piece. 28 January 2021
Novartis’ Steven Baert, chief people and organization officer, and Elizabeth Theophille, chief technology transformation officer, provide an Expert View predicting what will dictate developments in the pharmaceutical and healthcare industries in 2021. 19 January 2021
Rick Brar, chief executive at Brains Bioceutical, considers the implications of the UK’s departure from the European Union (EU) in an Expert View piece. 8 January 2021
Clive Glover, director, strategy, Pall Corporation, provides an Expert View on what recent developments mean for the industry and the importance of safety in gene therapy manufacturing. 10 December 2020
Lawsuits for patent infringement require a showing that an accused product or process includes each and every element of an asserted claim, write Jonathan Roses, counsel, Wolf, Greenfield & Sacks, and Alexander Lee, associate, Hoffmann Eitle, in an Expert View piece. 20 November 2020
As the coronavirus pandemic continues, the previously out-of-favor global biotech and life sciences sector is seeing significant investment and a reputational boost, writes Maxim Jacobs, managing partner and director of research at Edison Investment Research, in an Expert View. 4 November 2020
Jonathan Roses, counsel Wolf, Greenfield & Sacks and Matthew Birkett, partner, Hoffmann Eitle, provide an Expert View on general treatment of salt and polymorphic forms in the US Patent and Trademark Office, the European Patent Office and the courts. 23 October 2020
Japan remains on balance an attractive pharmaceutical market, with favorable volume dynamics, generally attractive pricing and broad and unfettered market access, writes Patrick Branch from LEK Consulting, in an Expert View piece. 7 October 2020